Qizhi Tang, Ph.D., is a professor of immunology in the Diabetes Center, the Department of Surgery, the Gladstone Institute of Genomic Immunology, and the Institute of Regenerative Medicine at the University of California, San Francisco (UCSF).  Early in her career as a postdoctoral fellow, she was among the first to demonstrate potent, durable, and selective suppression of anti-islet autoimmunity using antigen-specific Tregs. In her own lab, she focused on developing Treg cell therapies by investigating Treg control of immune responses and translating insights from basic mechanistic research to therapies in humans.  She collaborated extensively to design and implement 10 Treg-based clinical trials in autoimmune diseases and organ transplantation.  Currently, pre-clinical research in her lab focuses on investigating human Treg antigen specificity, persistence, and lineage stability to inform the design of next-generation Treg therapy for autoimmune diseases and transplant rejection.